New Hypertension Guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society

Abstract

A joint initiative between the National Institute for Health and Clinical Excellence (NICE) and the British Hypertension Society (BHS) has led to the publication of new guidelines for the management of hypertension in the community. Recent trial evidence highlighting the increased incidence of new-onset diabetes in those exposed to beta-blocker-based treatment regimens, with or without diuretics, compared with those based on calcium channel blockers (CCBs) or angiotensin-converting enzyme (ACE-Is) inhibitors has led to a recommendation that in the uncomplicated patient, beta-blockers are no longer considered suitable options for first-line therapy. Together with mounting A evidence that age and ethnicity dictate blood pressure (BP) responsiveness to different classes of antihypertensive drugs, the ACD algorithm is now proposed (formerly ABCD), with ACE inhibitors (ACE-Is) (or angiotensin receptor blockers [ARBs] when ACE-Is are poorly tolerated) preferred in younger patients and or patients and CCBs or diuretics preferred for older patientsand in black patients of any age. Pathophysiological considerations have influenced proposals for combination therapies with CCBs or diuretics added to older patients. Health economic analyses have ACE-Is in younger patients and vice versa in clearly indicated the cost effectiveness of CCBs which are now elevated to equal standing with diuretics in older patients.

Keywords

Hypertension Guidelines British Hypertension Society NICE

Get full access to this article

View all access options for this article.

References

Kearney PM , Whelton M. , Reynolds K. , Muntner P. , Whelton PK , He J. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23.

Wolf-Maier K. , Cooper RS , Kramer H. et al. Hypertension treatment and control in five European countries, Canada, and the United States . Hypertension 2004;43(1):10-17. Epub 2003, Nov 24.

Williams B. , Poulter NR , Brown MJ et al. BHS guidelines working party, for the British Hypertension Society . British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004;328(7440):634-40.

National Institute for Health and Clinical Excellence (NICE) website - http://www.nice.org.uk/CG034guidance

European Society of Hypertension-European Society of Cardiology Guidelines Committee 2003. European Society of Hypertension-European Society of Cardiology guidelines for R the management of arterial hypertension. J Hypertens 2003;21(6):1011-53.

Chobanian AV , Bakris GL , Black HR et al. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC7 Report. Hypertension. 2003 ;42(6):1206-52. Epub 2003 Dec 1.

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.

Dahlöf B. , Sever PS , Poulter NR , Wedel H. , Beevers DG , Caulfield M. , Collins R. , Kjeldsen SE , Kristinsson A. , McInnes GT , Mehlsen J. , Nieminen M. , O'Brien E. , Ostergren J. ; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906.

Verdecchia P. , Reboldi G. , Angeli F. , et al. Adverse Prognostic significance of new diabetes in treated hypertensive subjects. 2004;43:963-69.

10.

Julius S. , Kjeldsen SE , Weber M. , Brunner HR et al. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363(9426):2022-31.